Progyny (NASDAQ:PGNY) Director Sells $137,445.00 in Stock

Progyny, Inc. (NASDAQ:PGNY) Director Kevin Gordon sold 5,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total transaction of $137,445.00. Following the sale, the director owned 9,318 shares in the company, valued at $232,856.82. The trade was a 37.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Progyny Stock Performance

Shares of PGNY stock opened at $25.56 on Monday. The stock has a market capitalization of $2.00 billion, a P/E ratio of 33.19, a PEG ratio of 1.36 and a beta of 1.03. The firm’s 50 day moving average is $19.83 and its 200 day moving average is $22.24. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. During the same period in the prior year, the company posted $0.17 EPS. Progyny’s revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities analysts predict that Progyny, Inc. will post 1.12 EPS for the current year.

Progyny declared that its board has approved a share buyback program on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 10.3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Progyny

A number of institutional investors and hedge funds have recently made changes to their positions in PGNY. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Progyny in the fourth quarter worth $25,000. Federated Hermes Inc. raised its position in shares of Progyny by 147.3% in the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after buying an additional 819 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares in the last quarter. Quarry LP raised its position in shares of Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after buying an additional 3,427 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Progyny in the second quarter worth $77,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Truist Financial raised their price target on Progyny from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, May 11th. BTIG Research cut their price target on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Canaccord Genuity Group raised Progyny from a “hold” rating to a “buy” rating and raised their price target for the stock from $19.00 to $30.00 in a report on Tuesday, May 19th. Finally, KeyCorp cut their price target on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.55.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.